What Does a Microdose of Lupron Do for IVF?

A microdose of Lupron (leuprolide acetate) given at the start of an IVF cycle triggers a brief surge of your body’s own reproductive hormones, which helps recruit more follicles and improves the response to stimulation medications. This approach, called the “microdose flare” protocol, was developed specifically for women whose ovaries respond poorly to standard IVF stimulation. The strategy takes a drug normally used to suppress hormones and, by giving it in tiny amounts at a precise moment, flips its effect into a short-lived boost instead.

How the Flare Effect Actually Works

Lupron belongs to a class of drugs that mimic a natural brain hormone called GnRH (gonadotropin-releasing hormone). At full therapeutic doses given over days or weeks, it shuts down the pituitary gland’s production of LH and FSH, the hormones that drive ovulation and follicle growth.¹ That suppressive effect is exactly what clinicians use in long-protocol IVF to prevent a premature LH surge. But the suppression does not happen instantly. In the first day or two after any GnRH agonist hits the pituitary, there is actually a burst of LH and FSH release before the gland quiets down.

The microdose flare protocol exploits that initial burst on purpose. By using a very small dose, typically around 40 to 50 micrograms injected twice daily, the pituitary releases a wave of FSH and LH that helps wake up follicles at the very start of the stimulation cycle. Because the dose is so small, the suppressive phase that follows is mild and brief, so it does not counteract the stimulation drugs (gonadotropins) that are added the next day.² The result is a kind of hormonal head start: your own body’s FSH kicks off follicle development, and then injectable gonadotropins take over to push those follicles the rest of the way.

Who the Microdose Flare Protocol Is Designed For

This protocol exists primarily for “poor responders,” a term fertility clinicians use for women whose ovaries produce few eggs despite aggressive stimulation. Criteria vary by clinic, but poor responders are generally defined as patients who have had previous cycles with low estrogen levels, four or fewer mature follicles, or prior failed stimulation with standard long-protocol Lupron or gonadotropin-only cycles.³ These patients often have diminished ovarian reserve, meaning their pool of remaining eggs is smaller than expected for their age.

For someone with a normal or robust ovarian response, the microdose flare protocol is rarely needed. Standard long-protocol Lupron or an antagonist protocol usually produces plenty of eggs, and the added flare could actually cause problems by over-stimulating the ovaries. The microdose approach is specifically tuned for ovaries that need every possible nudge to produce a usable number of eggs.

Age factors in as well. Some classification systems group poor responders by whether they are younger with low ovarian reserve or older with low reserve, and the microdose protocol has been studied across both groups.⁴ But the unifying thread is a history of poor response, not age alone.

What the Protocol Looks Like Day by Day

The microdose flare protocol follows a fairly tight timeline. It typically begins on cycle day 2 or 3, with the patient injecting a small dose of leuprolide acetate (commonly 50 micrograms, or 0.05 mg) subcutaneously twice a day. The following day, high-dose gonadotropin injections begin and continue alongside the microdose Lupron throughout the stimulation phase.²

Monitoring with blood draws and ultrasounds tracks follicle growth and hormone levels. When at least two leading follicles reach about 17 mm and estrogen levels are adequate, a trigger shot of hCG is given, and egg retrieval is scheduled roughly 36 hours later.² The overall stimulation phase typically lasts 8 to 12 days, similar to other IVF protocols, though individual variation is common.

Many clinics have patients take oral contraceptive pills (OCPs) for a few weeks before starting the microdose flare. This “priming” step synchronizes follicle development and helps prevent one dominant follicle from racing ahead. Research shows that OCP pretreatment suppresses the early FSH rise before Lupron begins but does not blunt the FSH flare that the microdose triggers. It does dampen the LH component of the flare, which may actually be beneficial by reducing the risk of premature luteinization.⁵

Does the Flare Response Always Happen?

Not every patient who receives a microdose of Lupron experiences a measurable hormone flare, and this is a point that catches some patients and clinicians off guard. Research has examined whether the size of the flare predicts IVF success, and the findings are somewhat surprising: the presence or absence of a noticeable flare does not consistently correlate with how the cycle turns out.⁶

What does seem to matter, though, is practical. Women who do mount a flare response tend to require higher doses of gonadotropins and more days of stimulation than those who do not. That observation can help a clinic adjust its starting gonadotropin dose when using this protocol, potentially reducing the chance of cancelling a cycle for poor response.⁶ So while the flare is the theoretical engine of this protocol, real-world success seems to depend on the overall stimulation strategy rather than on one measurable hormone spike.

How Microdose Lupron Compares to Antagonist Protocols

The main rival to the microdose flare for poor responders is the GnRH antagonist protocol, which uses a different class of drug (like ganirelix or cetrorelix) to prevent premature ovulation. Instead of causing and then exploiting a hormone flare, antagonist protocols simply block the LH surge directly, starting partway through stimulation. Each approach has trade-offs, and the clinical literature does not show a clear winner for all patients.

In a study comparing the two approaches in poor responders, the microdose flare group retrieved more mature oocytes on average (about 3.6 versus 2.8) and had a higher implantation rate (roughly 28% versus 19%). Fertilization rates were similar between the two groups, and while the clinical pregnancy rate trended higher with the microdose protocol (about 20% versus 14%), that difference was not large enough to be statistically definitive.² A separate randomized study found a similar pattern, with the microdose group producing more high-quality embryos and a higher implantation rate (22% versus 11%), even though overall pregnancy rates were not significantly different.⁷

One caveat to the microdose approach is that it tends to require slightly more gonadotropin medication overall, which adds cost. In the study above, the microdose group used an average total gonadotropin dose of about 3,814 IU compared to roughly 3,539 IU in the antagonist group.² Given that gonadotropins are one of the most expensive components of an IVF cycle, this is worth factoring in. Some researchers have noted that the antagonist protocol may be a reasonable alternative on the basis of cost and convenience, since it involves fewer injections and a slightly simpler schedule.⁸

How It Compares to the Standard Long Lupron Protocol

If you have been through a standard long-protocol IVF cycle, you may have already used Lupron at a higher dose starting in the luteal phase (the second half) of the cycle before stimulation. That long protocol uses Lupron’s suppressive effect on purpose: it quiets the pituitary for a week or more before gonadotropins are added, giving the clinic complete control over timing and preventing a premature LH surge. For normal or high responders, this works well.

For poor responders, though, that extended suppression can be counterproductive. The ovaries, already sluggish, may become so quiet under long-protocol Lupron that stimulation medications struggle to produce adequate follicle growth. The microdose flare was developed specifically to avoid this problem, capturing the initial upregulatory burst while minimizing the suppressive tail.² Early studies of the microdose approach in poor responders showed improved estrogen responses, more oocytes retrieved, and fewer cancelled cycles compared to what these patients had experienced on standard protocols.⁹

One study comparing microdose flare, antagonist, and long-protocol approaches head to head in patients who responded poorly in their first cycle found that clinical pregnancy rates were numerically highest in the long-protocol group (about 21%) compared to the microdose (about 13%) and antagonist (about 13%) groups, but the differences were not statistically significant.¹⁰ Results like these underscore why protocol choice for poor responders remains a genuinely unsettled question. No single approach is universally best, and individual patient factors like age, ovarian reserve markers, and prior cycle history matter as much as the protocol name on the chart.

Ultra-Low-Dose and Very-Low-Dose Variations

In recent years, some clinics have pushed the dosing even lower than the traditional microdose, creating what are called “ultra-low-dose” and “very-low-dose” Lupron protocols. Instead of the standard 0.05 mg (50 micrograms) twice daily, these approaches use doses in the range of 0.05 to 0.1 mg once daily, or even 0.1 to 0.2 mg daily that gets tapered down. The idea is to provide just enough pituitary stimulation or mild suppression to coordinate follicle growth without the flare-then-suppress roller coaster.⁴

These newer variations reflect the broader trend in reproductive medicine toward individualizing stimulation protocols rather than applying one formula to every poor responder. For younger patients with low reserve, the dose titration may look different than for older patients with the same low reserve, even when both are classified as poor responders. The evidence on whether ultra-low-dose protocols outperform the traditional microdose flare is still building, and there is no consensus yet. But the existence of these variations tells you something important about the field: clinicians recognize that even “microdose” is not always micro enough for some patients, and fine-tuning continues.

Practical Things to Know Before Starting a Microdose Flare Cycle

If your doctor recommends a microdose flare protocol, there are a few practical realities worth understanding ahead of time.

Injection frequency: You will likely give yourself two Lupron injections per day in addition to your gonadotropin injections, which means three or more shots daily for much of the stimulation phase. The Lupron injections are subcutaneous and use a small insulin-type syringe, so they are not painful, but the schedule is demanding.
OCP lead-in: Many protocols begin with two to three weeks of oral contraceptive pills before the stimulation cycle starts. If your clinic uses this approach, build that lead time into your planning.
Medication cost: The gonadotropin doses used in microdose flare protocols tend to be at the higher end, which increases the pharmacy bill. Ask your clinic for a cost estimate specific to the protocol before starting.
Monitoring intensity: The monitoring schedule is similar to other IVF protocols, typically involving blood draws and ultrasounds every one to three days during stimulation. Because poor responders can have unpredictable ovarian behavior, your clinic may adjust doses or timing more frequently than in a straightforward cycle.
Cycle cancellation: Even with the flare protocol, some poor responders will not produce enough follicles to proceed to retrieval. The microdose approach reduces cancellation rates compared to standard protocols for this population, but it does not eliminate the possibility.

Side effects from the microdose Lupron itself are generally mild and short-lived, because the dose is so small and the duration of use is limited to the stimulation window. Full-dose Lupron given for weeks can cause hot flashes, headaches, and mood changes due to estrogen suppression, but the microdose version rarely causes these symptoms at a noticeable level. Most of the side effects patients experience during a microdose flare cycle are attributable to the gonadotropin medications and the general physical process of ovarian stimulation, not the Lupron.

Endometriosis and Extended GnRH Agonist Use

One clinical scenario worth mentioning separately is endometriosis. Some patients with endometriosis undergoing IVF receive prolonged GnRH agonist therapy (full-dose Lupron given for weeks or months before stimulation) to quiet endometriosis lesions and improve the uterine environment. This is a fundamentally different use of the same drug. A study comparing this extended GnRH agonist pretreatment to standard protocols (including microdose flare regimens) in endometriosis patients found that the longer suppression approach produced higher ongoing pregnancy rates, around 80% versus roughly 54%, and a trend toward better implantation rates.¹¹

The takeaway is that the microdose flare is not always the right move even when Lupron is part of the plan. For endometriosis patients, the full suppressive power of Lupron given at higher doses over longer periods can be more beneficial than the quick flare approach. This is another example of why IVF protocol decisions are so individualized. The same drug, used differently, serves completely different clinical purposes.

Why There Is No Single “Best” Protocol for Poor Responders

If you have been reading through IVF forums or talking to other patients, you have probably noticed conflicting opinions about whether the microdose flare is better than an antagonist protocol, or whether the long protocol is secretly the right answer, or whether some newer minimal-stimulation approach is the future. The honest state of the evidence is that none of these approaches has proven clearly superior for all poor responders in large, well-designed trials. Studies tend to be small, and the patient populations are heterogeneous, which makes it hard to draw sweeping conclusions.

What the research does support is that the microdose flare consistently produces reasonable outcomes for poor responders and tends to yield more mature eggs and better implantation rates than antagonist protocols in many (though not all) direct comparisons. It also avoids the heavy suppression that makes the long protocol a poor fit for patients with diminished reserve. Whether those advantages translate into more babies born depends on a web of factors that no single protocol can control, including egg quality, embryo genetics, endometrial receptivity, and the skill of the lab handling the embryos.

The decision about which protocol to use is ultimately a conversation between you and your reproductive endocrinologist, informed by your specific history, your ovarian reserve markers, how your body responded to any previous cycles, and sometimes pragmatic considerations like cost and scheduling. The microdose Lupron flare is one of the most established tools for poor responders, and understanding what it does and why it exists puts you in a better position to have that conversation.